BRUCE A JULIAN, MD
Osteopathic Medicine at 19 St, Birmingham, AL

License number

Alabama 11679

Personal information

See more information about BRUCE A JULIAN at radaris.com

Name

Address

Phone

Bruce A. Julian

Birmingham, AL

(205) 822-6468

Bruce Julian

1280 Parliament Ln, Vestavia, AL 35216

Bruce Julian

1801 University Blvd, Birmingham, AL 35233

Bruce Julian

1600 7Th St, Birmingham, AL 35233

Organization information

See more information about BRUCE A JULIAN at bizstanding.com

Uab Hospital - Bruce A Julian MD

1802 6 Ave S, Birmingham, AL 35233

Categories:

Nephrology Physicians & Surgeons

Site:

uabhealth.org

Phone:

(205) 934-9999 (Phone)

Bruce Julian MD

2000 6 Ave S, Birmingham, AL 35233

Industry:

Internist

Phone:

(205) 934-9045 (Phone)

Bruce Allen Julian

Professional information

See more information about BRUCE A JULIAN at trustoria.com

Nephrologist At University Of Alabama At Birmingham

Position:

Nephrologist at University of Alabama at Birmingham

Location:

Birmingham, Alabama Area

Industry:

Higher Education

Work:

University of Alabama at Birmingham - Nephrologist

Bruce A Julian, Birmingham AL

Specialties:

Nephrologist

Address:

619 19Th St S, Birmingham, AL 35233

Education:

Washington University, School of Medicine - Doctor of Medicine
UK Healthcare Good Samaritan Healthcare - Fellowship - Nephrology (Internal Medicine)

Board certifications:

American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Nephrology (Internal Medicine)

Dr. Bruce A Julian - MD (Doctor of Medicine)

Hospitals:

UAB Health System Nephrology
1530 3Rd Ave S SUITE 643, Birmingham 35294
1900 University Blvd SUITE THT643, Birmingham 35233
Highlands Medical Center
380 Woods Cove Rd, Scottsboro 35768
University of Alabama Hospital
1802 6Th Ave South, Birmingham 35233
UAB Health System Nephrology
1530 3Rd Ave S SUITE 643, Birmingham 35294
1900 University Blvd SUITE THT643, Birmingham 35233
Highlands Medical Center
380 Woods Cove Rd, Scottsboro 35768
University of Alabama Hospital
1802 6Th Ave South, Birmingham 35233

Education:

Medical Schools
Washington University St Louis
Graduated: 1975

Regulation Of Osteoclast Formation By Inhibition Of Osteoblastic Stem Cell Factor

US Patent:

6248326, Jun 19, 2001

Filed:

Sep 10, 1998

Appl. No.:

9/150797

Inventors:

Harry C. Blair - Mountain Brook AL
Sai-Sai Dong - Alpine AL
Bruce A. Julian - Vestavia Hills AL

International Classification:

A61K 39395, C07K 1628, C07K 1618

US Classification:

4241391

Abstract:

The present invention provides an inhibitor of osteoblastic stem cell factor binding and/or activity, for example, an antibody or an antisense oligonucleotide. Also provided are pharmaceutical compositions comprising these inhibitors of osteoblastic stem cell factor binding and/or activity. Further provided is a method of regulating the activity of osteoclasts, comprising the step of: inhibiting the binding and/or activity of osteoblastic stem cell factor.

Diagnosing And Treating Iga Nephropathy

US Patent:

2012026, Oct 18, 2012

Filed:

May 26, 2010

Appl. No.:

13/321025

Inventors:

Hitoshi Suzuki - Tokyo, JP
Run Fan - Charlottesville VA, US
Bruce A. Julian - Birmingham AL, US
Jan Novak - Pelham AL, US
Zina Moldoveanu - Birmingham AL, US
Zhixin Zhang - Omaha NE, US
Milan Tomana - Birmingham AL, US
Jiri Mestecky - Birmingham AL, US
Robert J. Wyatt - Memphis TN, US
Yasuhiko Tomino - Tokyo, JP
Yusuke Suzuki - Tokyo, JP
Stephen Olson - Rockville MD, US

International Classification:

A61K 39/395, G01N 33/566, C12Q 1/68, G01N 21/76, C07K 16/00, C07K 16/42, A01K 67/00, A61K 35/16, A61P 13/12, G01N 21/78, C40B 30/04

US Classification:

800 9, 435 792, 435 71, 435 611, 435 612, 506 9, 4241311, 5303872, 424530, 5303871

Abstract:

Provided are methods of diagnosing IgA nephropathy in a subject. Optionally, the methods comprise isolating an IgG from the subject and determining whether the IgG binds to a galactose-deficient IgA1. Optionally, the methods comprise providing a biological sample from the subject and detecting in the sample a mutation in a IGH gene, wherein the mutation is in a nucleotide sequence encoding a complementarity determining region 3 (CDR3) of a IGH variable region. Optionally, the methods comprise determining a level of IgG specific for a galactose-deficient IgA1 in the subject. Also provided are methods of treating or reducing the risk of developing IgA nephropathy in a subject.